Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Ointment Clear all
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

NCT05206604
View directory record Official record
Conditions
Healthy
Interventions
PF-07295324, PF-07259955
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 4:29 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Study of SOR007 Ointment for Actinic Keratosis

NCT03083470
View directory record Official record
Conditions
Actinic Keratosis
Interventions
SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
Drug · Other
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
45 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

NCT02068352
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Vehicle ointment
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042
View directory record Official record
Conditions
Healthy
Interventions
Within-Subject Active vs. Placebo Topical Applications
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 25, 2026, 4:29 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

NCT03096444
View directory record Official record
Conditions
Pruritus
Interventions
Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream
Drug · Combination Product
Lead sponsor
Gil Yosipovitch
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

NCT00645671
View directory record Official record
Conditions
Ocular Inflammation
Interventions
0.5% Loteprednol Etabonate Ophthalmic Ointment, Vehicle of Loteprednol Etabonate Ophthalmic Ointment
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

NCT02960997
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
Interventions
Sirolimus, 2%, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

NCT02950922
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment
Drug · Other
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
12 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

NCT02118766
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Results available

Plaque Psoriasis Study in Pediatric Subjects

NCT02186665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
calcitriol ointment, placebo comparator
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 25, 2026, 4:29 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075
View directory record Official record
Conditions
Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Interventions
GX-03, Vehicle
Combination Product · Other
Lead sponsor
Turn Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
View directory record Official record
Conditions
Healthy
Interventions
diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 25, 2026, 4:29 PM EDT
Terminated Phase 2 Interventional

Green Tea Extract in Treating Patients With Actinic Keratosis

NCT00005097
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
Polyphenon E and Placebo
Drug
Lead sponsor
Frank Meyskens
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
39
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438
View directory record Official record
Conditions
Acne Rosacea
Interventions
ACCU-D1, Vehicle
Drug
Lead sponsor
Accuitis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 25, 2026, 4:29 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 25, 2026, 4:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

NCT05688735
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Isosorbide Diester Moisturizer, Control Moisturizer
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 25, 2026, 4:29 PM EDT